Author(s):
Darshan J. Pandya, Sejal G. Patel, Ujashkumar A. Shah, Chhaganbhai N. Patel, Khushbu Patel
Email(s):
djpandya11998@gmail.com
DOI:
10.52711/0974-360X.2026.00323 
Address:
Darshan J. Pandya1, Sejal G. Patel2, Ujashkumar A. Shah2, Chhaganbhai N. Patel3, Khushbu Patel3
1Research Scholar, Faculty of Pharmacy, Sankalchand Patel University, S. K. Campus, Kamana Cross Road, Visnagar - 384315, Gujarat, India.
2Department of Quality Assurance and Pharmaceutical Chemistry, Nootan Pharmacy College, Sankalchand Patel University, S. K. Campus, Kamana Cross Road, Visnagar-384315, Gujarat, India.
3Department of Quality Assurance and Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Near Arvind Bag, Mahesana - 384001, Gujarat, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
A new simple stability indicating reverse phase liquid chromatography method was developed by employing Quality by Design (QbD) approach for the simultaneous determination of Dapagliflozin and Linagliptin. Within QbD paradigm, the present study aimed to establish the optimization of the RP-HPLC (Reverse phase high performance liquid chromatography) by means of design of experiments and response surface mythology like, Centre composite design (CCD) in order to achieve a good separation and resolution. The developed method is effective to separate Dapagliflozin and Linagliptin with a good chromatographic resolution of 5.272. Chromatographic separation was acquired with column C8 Inertsil column (250 × 4.6 mm, 5 µm) at flow rate 1.0 mL/min with the mobile phase consists of methanol and water (85:15 % v/v). The detection of Dapagliflozin and Linagliptin was carried out at 225 nm. The proposed method was validated according to ICH guidelines. The method was linear in range of 2.5-15 µg/mL and 1.25-7.5 µg/mL of Dapagliflozin and Linagliptin respectively and recovery were in the range of 99% to 100%. The degradation product found in stress patterns were well separated among the drug compounds. The method was validated to be specific, rapid, precise and robust for routine analysis in its pharmaceutical dosage form.
Cite this article:
Darshan J. Pandya, Sejal G. Patel, Ujashkumar A. Shah, Chhaganbhai N. Patel, Khushbu Patel. Stability indicating RP-HPLC Method Development and Validation of Dapagliflozin and Linagliptin in Tablet Dosage form by QbD Approach. Research Journal Pharmacy and Technology. 2026;19(5):2245-2. doi: 10.52711/0974-360X.2026.00323
Cite(Electronic):
Darshan J. Pandya, Sejal G. Patel, Ujashkumar A. Shah, Chhaganbhai N. Patel, Khushbu Patel. Stability indicating RP-HPLC Method Development and Validation of Dapagliflozin and Linagliptin in Tablet Dosage form by QbD Approach. Research Journal Pharmacy and Technology. 2026;19(5):2245-2. doi: 10.52711/0974-360X.2026.00323 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-5-44
REFERENCES:
1. “Dapagliflozin”, Drug Bank. [cited 2024 Feb 26]. Available from: https://go.drugbank.com/drugs/DB06292
2. Dhillon SO, “Dapagliflozin: A Review in type 2 Diabetes”, Adis., 2019; 79: 1135- 1146.
3. Zargar AB, Trailokya AB et al, “Current Role of Dapagliflozin in Clinical Practice”, JAPI., 2021, 69.
4. “Linagliptin”, Drug Bank. [cited 2024 Feb 26]. Available from: https://go.drugbank.com/drugs/DB08882
5. Hoimark LE, Rungby JO et al, “Potential role of Linagliptin as an oral once-daily treatment for patients with type-2 diabetes”, Dovepress., 2012; 5: 295-302.
6. “Dapagliflozin”, National Library of Medicine. [cited 2024 Feb 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/ Dapagliflozin
7. “Linagliptin”, National Library of Medicine. [cited 2024 Feb 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Linagliptin
8. ICH, Q8(R2), Harmonized Tripartite Guideline, Pharmaceutical Development. Available from:https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.
9. Astha P. Sanyal, Khushbu K. Patel, Ushma B. Patel and Dr. Chhaganbhai N. Patel. Analytical Method Development and Validation for Estimation of Saroglitazar Magnesium in Pharmaceutical Dosage Form by Quality by Design Approach. World Journal of Pharmacy and Pharmaceutical Sciences. 2020; 9(4): 1267-1281.
10. Jinal A Goswami, Zeel. M. Modi, Khushbu Patel, Dr. C.N. Patel. Review on Implementation of Quality by Design. International Journal of Innovative Science and Research Technology. 2024; 9(2): 544-548.
11. ICH, Q1A(R2): Stability Testing of New Drug Substance and Drug Product. Available from:https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf.
12. Priyadarshini Chaudhari, Mayur Prajapati, Nidhi Patel, Dhruv Patel, Anjali Prajapati, and Khushbu Patel. Newer Approaches for Analytical Method Validation of Anti Diabetic Agents: A Review. International Journal of Innovative Science and Research Technology. 2024; 9(12): 650-669.
13. Harshil R. Thakkar, Mohammadarsh B. Mansuri, Dr. Khushbu Patel, Dr. C. N. Patel. Dapagliflozin Analysis: A Review on Chromatography and Spectroscopic Methods. International Journal of Innovative Science and Research Technology. 2025; 10(1): 1985-1996.
14. Khushbu K. Patel, Arati M. Patel, C. N. Patel. A new simple RP-HPLC Method development, Validation and Forced degradation studies of Bilastine. Asian Journal of Pharmaceutical Analysis. 2021; 11(3): 183-7.
15. Patel, Khushbu, et al. Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of Evogliptin tartrate by analytical quality by design. Future Journal of Pharmaceutical Sciences. 2023; 9,57; 1-12.
16. Pandya, D. J., et al. Development and Validation of Bilastine in Tablet Dosage Form by Quality by Design Approach. Indian Journal of Pharmaceutical Sciences, 2024; 683(2): 683–691.
17. Dhruvi Modi, Payal Chauhan, Mansuri Seemabanu, Savitree Giri, Khushbu Patel, C. N Patel. Quantitative Estimation of Gallic Acid in Triphala Tablets by UV Spectrophotometric Method. Asian Journal of Pharmaceutical Analysis. 2024; 14(3): 122-6.
18. Priyadarshini Chaudhari, Mayur Prajapati, Jaimin Suthar, Vishvesh Panchal, Khushbu Patel, C. N. Patel. Spectrophotometric Method Development and Validation for Simultaneous Estimation of Metformin Hydrochloride and Evogliptin Tartrate in Pharmaceutical Dosage Form. Asian Journal of Pharmaceutical Analysis. 2025; 15(1): 45-0.
19. Krishna RV, Pallavi A, Sathyanarayana B. Stability indicating HPLC method development and validation for simultaneous estimation of Metformin, Dapagliflozin and Saxagliptin in bulkdrug and pharmaceutical dosage form. Biomedical Chroma. 2022, 36.
20. Singh N, Bansal P, Maithani M, Chauhan Y. Development and validation of a stability-indicating RP-HPLC method for simultaneous determination of dapagliflozin and saxagliptin in fixed-dose combination. New J. Chem. 2018; 42: 2459-2466.
21. Tarekegn TU, A. Krishnamanjari P. New validated stability-indicating RP-HPLC method for the simultaneous determination of Metformin hydrochloride, Linagliptin and Empagliflozin in bulk and pharmaceutical dosage forms. Int. J. App. Pharm. 2022; 14: 68-76.
22. Saroj Gajare, Vedantika Das, Ashwini Sambherao, Amar Zalte, Ravindra B. Saudagar. Development and Validation of Linagliptin and Metformin hydrochloride in Bulk and Combined Tablet Dosage Form by using UV Spectrophotometric Method. Asian Journal of Pharmaceutical Analysis. 2017; 7(2): 141-144.
23. M. Mallikarjuna, C. Guru Sudhakar, K. Siva Shankar, SK. Abid, P. Rameeja. Development and Validation of a New Method for the Simultaneous Estimation of Metformin and Linagliptin in Bulk and Dosage form by using UV–Spectrophotometry. Asian Journal of Chemistry and Pharmaceutical Research. 2018; 6(1): 58-72.
24. Khushbu Patel, C. N. Patel, Henee Patel. QbD based RP-HPLC Method Development and Validation for Estimation of Evogliptin Tartrate in Pharmaceutical Dosage Form. International Journal of Pharmaceutical Sciences and Nanotechnology. 2025; 17(6): 7688-7696.
25. Khushbu Patel, Ujashkumar A. Shah, Hirak V. Joshi, Jayvadan K. Patel, Chhaganbhai N. Patel. QbD Stressed Development and Validation of Stability-Indicating RP- HPLC Method for the Simultaneous Estimation of Linagliptin and Metformin HCl in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2022; 15(5): 1917-3.
26. Gunasekar M, Ahmed MI, Zeyad MA. Stability-Indicating RP-HPLC Method Development for Simultaneous Determination and Estimation of Dapagliflozin in Raw and Tablet Formulation. Chemistry Res. J. 2018; 3(2): 159-164.
27. Laxman B, Yojana K, Chaitali K, Shivam K, Sagar M, Rahul KG. A Rapid and Sensitive stability indicating Rp-HPLC method development for the quantitative analysis of empagliflozin and linagliptin in bulk and synthetic mixture. Int. J. of Health Sci. 2022; 6(S3): 5526–5538.
28. Sohan S. Chitlange, Mohammed Imran, Kiran Bagri, DM Sakarkar. A stability-indicating reverse phase high performance liquid chromatography method for the simultaneous determination of ramipril and valsartan in pharmaceutical dosage form. Research J. Pharm. and Tech. 2008; 1(3): 215-217.
29. B. Thangabalan, M. Salomi, N. Sunitha, S. Manohar Babu. Development of validated RP-HPLC method for the estimation of Itraconazole in pure and pharmaceutical dosage form. Asian J. Pharm. Ana. 2013; 3(4): 119-123.
30. N. Sunitha, L. Sindhura, B. Thangabalan, S. Manohar Babu. Development and Validation of RP–HPLC Method for Simultaneous Estimation of Cefepime and Tazobactam in Injection Formulation. Asian J. Pharm. Ana. 2013; 3(4): 131-137.
31. H.I. Pawar, Lata Kothapalli, Asha Thomas, R.K Nanda, Shivaji Mare. Simultaneous RP-HPLC Method for Estimation of Ezetimibe and Fenofibrate in Synthetic mixture. Research J. Pharm. and Tech. 2008; 1(1): 25-28.
32. Darshak P, Ujashkumar S, Jayvadan P, Darshana P, Pavan P. A Stability Indicating RP-HPLC Method Validation for Simultaneous Estimation of Linagliptin and Empagliflozin in Pharmaceutical Dosage Form. Cur. Aspe. In Pharma. Rese. And Dev. 2022; 8: 128-143.
33. ICH, Q2(R1): Validation of Analytical Procedure: Text and Methodology. Available from: https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.